Companies › VitsGen Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 177Lu-PSMA-VG01 PSMA-targeting radioligand (lutetium-177 labeled) | FOLH1 | Phase 1 | PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07660211 | 177Lu-PSMA-VG01 | Phase 1 | PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) | Oncology | May 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.